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Hypertensive left ventricular failureTo study the long-term cardiovascular and non-cardiovascular outcomes among patients admitted with hyper-
tensive crisis. A total of 297 (145 diabetics, 152 nondiabetics) patients with hypertensive crisis were followed
up for a median of 30months. Fatal and nonfatal events were tracked. The traced events deﬁned as hypertensive
urgency, acute coronary syndrome, left ventricular failure, atrial ﬁbrillation, cerebrovascular or renal failurewere
consecutively analyzed during the follow-up.Overall, 140 (47%) patients had nonfatal clinical events (115 dia-
betics and 25 nondiabetics); 37 (12%) patients had fatal clinical events (26 diabetics and 11 nondiabetics). The
rate of fatal and nonfatal eventswas signiﬁcantly higher in diabetics. Themean time of survival was 25.7months,
with the shortest periods for stroke and left ventricular failure. For nondiabetic participants, themean time of sur-
vival was 31months. Cox regression analysis identiﬁed diabetesmellitus, acute left ventricular failure, stroke and
renal impairment as predictors of mortality. In conclusion, hypertensive crisis is associated with a markedly in-
creased risk for subsequent cardiovascular morbidity and mortality, especially among diabetics who present
with heart failure.
© 2015 TheAuthors. Published by Elsevier Ireland Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hypertensive crisis is deﬁned as acute marked elevation of blood
pressure, SBP ≥ 180 mm Hg and/or DBP ≥ 120 mm Hg. Hypertensive
emergency is diagnosed, when there is acute target damage and hyper-
tensive urgency when the latter is absent [1,2]. Previously we studied
the behavior of hypertensive crisis in our community [3–6]. The clinical
presentation of hypertensive crisis between diabetics and nondiabetics
was compared [4]. Patients with diabetes exhibited higher rates of
hypertensive emergency, particularly, left ventricular failure [4]. There
is little if any knowledge of whether the prognoses and outcomes of
hypertensive crisis differ between diabetics and nondiabetics. In
this study, we aimed to discover the clinical outcomes of hypertensive
crisis in both diabetics and nondiabetics beyond their initial clinical
presentation.edicine department, Salmaniya
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land Ltd. This is an open access article2. Methods
All patients age above 18 years, visited the accident and emergency
department with hypertensive crisis for a period of 6 months, from 1st
June 2010 till 31st December 2010 were consecutively included.
Patients with end stage renal failure requiring renal replacement thera-
py were excluded. Data on 297 patients were collected, 145 patients
were diabetics, and 152 were nondiabetics. The initial comparison of
their modes of presentation, types of hypertensive crises and associated
comorbidities were published earlier [4].
These patients were followed for a period of 32 months from their
initial presentation. Cardiovascular and cerebrovascular events requir-
ing admission, development or worsening of renal failure requiring
admission and commencement of renal replacement therapy were
tracked using electronic data records along with chart retrieval.
Mortality was documented based on electronic medical records and
patient death certiﬁcates. Causes of death were retrieved from the
ofﬁcial death certiﬁcates. To validate the status of patients who were
lost during follow-up, phone calls at the time of data collection were
made to gather meticulous information regarding admissions and
deaths. The time from the initial hypertensive crisis presentation until
the occurrence of each event was documented.under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Characteristics of 297 patients included, among two groups.
Characteristic Non-diabetics
(n = 152)
Diabetics
(n = 145)
P
value
Demography
Female sex [no.] (%) 49 (32.2) 60 (41.4) 0.10
Age [no.] (%) b0.01
b45 49 (32.2) 10 (6.9)
45–65 81 (53.3) 84 (57.9)
N65 22 (14.5) 51 (35.2)
Bahraini nationality [no.] (%) 83 (54.6) 106 (73.1) b0.01
Risk factors
Smoker [no.] (%) 52 (34.2) 39 (26.9) 0.17
Alcohol drinker [no.] (%) 13 (8.6) 10 (6.9) 0.59
High lipid [no.] (%) 56 (36.8) 102 (70.3) b0.01
Renal = 1 [no.] (%) 26 (17.1) 46 (31.7) b0.01
Ejection fraction [mean]
(range)
0.57 (0.20–0.80) 0.54 (0.20–0.80) 0.21
Mortality–dead [no.] (%) 11 (7.2) 26 (17.9) b0.01
Median follow-up time [months]
(range)
30 (0.5–32) 24 (0.3–28) b0.01
Blood pressure
Systolic [mean mm Hg] (SD) 199.6 (±21.9) 200.8 (±20.6) 0.62
Diastolic [mean mm Hg] (SD) 114.1 (±18.0) 108.1 (±17.5) b0.01
Pulse pressure [mean mm Hg]
(SD)
85.5 (±22.4) 92.7 (±21.5) b0.01
HBA1c [no. N53 mmol/l] (%) 117 (80.7)
Bold values represent the signiﬁcant P values among all variables tested.
Signiﬁcant P value b 0.05.
Table 2
Frequency of fatal and non fatal events across two groups during follow up period.
Non-diabetics
(n = 152)
Diabetics
(n = 145)
P value
Hypertensive urgency 115 57 0.001
Hypertensive emergency 37 86 0.001
Mortality (total fatal events) 11 26 0.001
Mortality across initial hypertensive crisis group
Hypertensive urgency 1 4 0.01
Acute coronary syndrome 2 3 NS
Left ventricular failure 3 15 0.001
Cerebrovascular 5 4 NS
Non fatal events
Hypertensive urgency 3 19 0.001
Acute coronary syndrome 6 12 0.001
Left ventricular failure 6 34 0.0001
Cerebrovascular 6 26 0.001
Renal failure 4 20 0.001
Atrial ﬁbrillation – 4 –
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tee on Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure (JNC 7) and the latest guidelines of the European Society of Hy-
pertension (ESH) guidelines of systolic blood pressure ≥180 mm Hg
and diastolic blood pressure of ≥120 mm Hg. The presence or absence
of acute target organ damage was the basis for deﬁning hypertensive
emergency versus urgency, respectively [1,2]. A patient was considered
to have diabetes if two readings of fasting blood glucose, taken on sep-
arate occasions, exceeded 7 mmol/L, if symptoms of diabetes occurred
with casual plasma glucose concentration ≥200 mg/dl (11.1 mmol/L),
or if the 2-hour post-load glucose level was ≥200 mg/dl (11.1 mmol/L)
during an oral glucose tolerance test (OGTT) [7]. Dyslipidemia (hyper-
cholesterolemia) was diagnosed if the total cholesterol level exceeded
200 mg/dl [8]. Acute stroke was deﬁned if the patient was admitted to
the hospital because of neurological deﬁcits for more than 24 h and the
radiology imaging of the brain revealed an ischemic or hemorrhagic
area [9]. The deﬁnition of acute coronary syndromewas based on typical
chest painwith electrocardiogram (ECG) changeswith orwithout elevat-
ed cardiac enzymes.We involved patients with unstable angina, non-ST-
elevation myocardial infarction (NSTEMI) and ST-elevation myocardial
infarction (STEMI) [10–12]. Left ventricular failurewas deﬁned according
to the Framingham criteria. The presence of two major criteria or one
major and twominor criteria was satisfactory for diagnosing left ventric-
ular failure or congestive heart failure [13]. Chronic renal impairmentwas
diagnosed when the estimated glomerular ﬁltration rate (GFR) was
b60 ml/min/1.73 m2 [14]. Acute renal failure and worsening kidney
function were validated using the RIFLE criteria for acute kidney injury
[15]. Patients were also included in the study if they had been admitted
to commence renal replacement therapy with either hemodialysis or
peritoneal dialysis at follow-up. New-onset atrial ﬁbrillation requiring
admission was validated by comparing the ECG conducted during the
admission with the patient's most recent ECG. Fast and slow atrial ﬁbril-
lation ventricular rates were included.
3. Statistical analysis
Quantitative data are presented as mean and standard deviation or
median and range. Categorical variables are given as absolute (counts)
and relative frequencies (percentage). For univariate comparison of
continuous variables, a t-test for two independent samples or Mann–
Whitney U-test was used. For univariate comparison of categorical
data χ2 tests were utilized. Mean survival times were calculated and
compared between diabetic and nondiabetic patients. Survival analyses
are due to Kaplan–Meier and log-rank tests. Hazard ratios and respec-
tive 95% conﬁdence intervals were calculated using Cox regression. In
univariate survival analyses the following variables were included:
presence or absence of diabetes mellitus, age, sex, nationality, systolic
blood pressure, diastolic blood pressure, pulse pressure, type of the
hypertensive crisis, smoking, renal impairment, alcohol consumption
and ejection fraction. If statistically signiﬁcant in the univariate analysis,
variables were included in an additional multiple Cox regression to ac-
count for possible confounding. Mortality was the dependent variable
and the independent variables were diabetes, nationality, type of crisis,
and renal impairment. Data processing was performed with MS Excel
2007 for Windows and IBM SPSS 20 for Windows. P values are two-
sided and subject to a signiﬁcance level of 0.05.
4. Results
The demographic data, comorbid conditions, blood pressure at initial
presentation, type of hypertensive crisis and mortality are shown in
(Table 1). Out of the 297 patients who presented with hypertensive
crisis, 145 were diabetics and 152 were nondiabetics. Diabetics were
older than 65 years of age and most were Bahrain citizens. Those
younger than 45 years were mainly nondiabetics. The median follow-
up was 30 months for nondiabetics [1–32] and 24 for diabetics (0–28)(Table 1). Hyperlipidemia was more common among diabetics, and
nearly one-third had renal impairment. At initial presentation, diabetics
had lower diastolic blood pressure, and hence their pulse pressures
were also higher (Table 1). Diabetics had higher mortality over the
follow-up period, 26 (17.9%) compared with 11(7.2%) among the non-
diabetics (P value b 0.01) (Table 1).4.1. Fatal and nonfatal cardiovascular and non-cardiovascular events
Of the 297 patients in our cohort, 177 events were observed
during the follow-up period, 37 fatal and 140 nonfatal. There were
26 fatal events among the diabetics and 11 among the nondiabetics
(P value b 0.01) (Table 2). Mortality attributed to cerebrovascular
events or to ACS was comparable between the diabetics and nondia-
betics during the follow-up period. Mortality caused by heart failure,
however, was much more prevalent among the diabetics upon follow-
up (Table 2). There were also signiﬁcantly more nonfatal events
among the diabetics (115 vs. 25) (P b 0.01). Of the nonfatal cardiovascu-
lar events, recurrent acute left ventricular failure was predominant
Table 3
Time to death in different hypertensive crisis groups among diabetics and nondiabetics
(data expressed as mean ± SD).
Non-diabetics Diabetics P value
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with nondiabetics (P b 0.0001) (Table 2). Of particular note was the
development of atrial ﬁbrillation in four patients with diabetes but not
in any of the nondiabetic patients (Table 2).(n = 152) (n = 145)
Overall 30.7 ± 0.4 25.7 ± 0.4 b0.01
Hypertensive urgency 31.8 ± 0.1 27.1 ± 0.5 b0.01
Hypertensive ACS 29.2 ± 1.8 25.5 ± 1.0 b0.01
Hypertensive LVF 28.5 ± 1.7 23.8 ± 0.8 b0.01
Hypertensive CVA 22.6 ± 4.6 23.2 ± 1.8 b0.01
ACS: acute coronary syndrome, LVF: left ventricular failure, CVA: cerebrovascular
accidents.4.2. Association between hypertensive crisis and subsequent fatal cardio-
vascular and non-cardiovascular events
The Kaplan–Meier plot demonstrating the probability of event-
free survival between diabetics and nondiabetics is presented in
(Fig. 1). As seen in the plot, the cumulative survival curve splits with-
in approximately 15 months of follow-up and continues to separate
(P value b 0.001).
The time-to-death intervals in the different hypertensive crisis
groups are depicted in (Table 3), with marked differences between
the diabetics and nondiabetics. The hazard survival analyses with time
to death are shown separately for diabetics and nondiabetics (Figs. 2
and 3). Similar plots that compare the probability of survival acrossFig. 1.Kaplan–Meier curves for the survival rate during study period. A: DMpatients' vs. nonDM
P b 0.001. D: Patients with normal renal function vs. renal impairment P b 0.01.the different age groups, types of hypertensive crisis, and normal vs.
impaired renal dysfunction are presented (Fig. 1).
Univariate Cox regression analysis identiﬁed diabetesmellitus, acute
left ventricular failure, stroke and renal impairment as independent pre-
dictors of mortality. The hazard ratio obtained through univariate Cox
regression analysis is shown in (Table 4).patients P b 0.001. B: Three age groups P value b 0.01. C: Initial hypertensive crisis groups
Fig. 2. Hazard survival analysis for diabetic patients across hypertensive crisis groups.
Table 4
Results from univariate Cox regression analyses to predict fatal events during study
period.
Hazard ratio 95% conﬁdence interval P value
Diabetes mellitus 3.46 1.65–7.24 b0.01
Age (N65 years) 10.86 2.55–46.32 b0.01
Nationality (non-Bahraini) 0.14 0.04–0.45 b0.01
Hypertensive LVF 13.63 5.05–36.81 b0.01
Hypertensive ACS 5.23 1.51–18.10 b0.01
Hypertensive CVA 17.09 5.71–51.16 b0.01
Renal impairment 0.39 0.21–0.75 b0.01
Dyslipidemia 0.75 0.38–1.44 0.38
Systolic blood pressure 1.00 0.98–1.01 0.92
Diastolic blood pressure 0.99 0.97–1.01 0.26
Pulse pressure 1.01 0.99–1.02 0.42
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emergency were predictors of mortality.
5. Discussion
This study compares the clinical outcomes of hypertensive crises
between diabetics and nondiabetics during almost three years of
follow-up. No such analysis has ever been reported in the literature.
At the initial clinical presentation, the diabetic patients were older and
had more comorbidities.
Themortality rate was 7% in patientswithout diabetes. Among these
patients, the majority of their presentation (75%) was hypertensive
urgency (115), Table 1. Vlcek et al. found 2% mortality among patients
with hypertensive urgency during 5 years of follow-up [16]. There
was no signiﬁcant mortality difference with the matched controls. The
latter were patients with elevated blood pressure and no hypertensiveFig. 3. Hazard survival analysis for nondiabetic patients across hypertensive crisis groups.urgency [16]. In the same study, a high number of nonfatal cardiovascu-
lar events in patients with hypertensive urgency compared with the
controls were observed [16]. Severely elevated blood pressure with no
acute target involvement would appear to have a worse prognosis
than was previously anticipated. The cautious immediate reduction of
blood pressure during hypertensive urgency should not underestimate
its serious cardiovascular outcome. Marked elevation in blood pressure
with evidence of proteinuria and/or left ventricular hypertrophy
stratiﬁes hypertensive urgency as high risk. As shown by Messerli
et al. [17], during the blood pressure progression of former US President
Franklin Roosevelt, when proteinuria and left ventricular hypertrophy
were detected, he died within a year from hypertensive crisis and
cerebral hemorrhage.
In our study, nondiabetic patients, although hypertensive urgency
was their dominant presentation, showed relatively a high mortality
rate of 7%. It is likely that their mortality was partly driven by the few
hypertensive emergencies and the evidence of renal impairment that
was observed in 17% of the patients. Diabetic patientswith hypertensive
crisis exhibited higher mortality (17.9%) and morbidity (Table 1). They
sustained more cardiovascular and non-cardiovascular insults through-
out the period of the study (Table 2). Diabetic patients were older and
had higher pulse pressure (Table 1). Wide pulse pressure is well docu-
mented in diabetics above the age of 50 years [18–20]. Pulse pressure
ampliﬁcation is considered a mechanical biomarker and can predict all
cause cardiovascular mortality [21–23].
Both fatal and nonfatal clinical outcomes were more prevalent
among patients with diabetes. Diabetes ampliﬁes individual cardiovas-
cular risk, and hence, its presence is considered equivalent to ischemic
heart disease [24,25]. In our data, hazard ratios and time to death
wereworse in diabeticswith hypertensive urgency than in nondiabetics
with acute coronary syndrome (Table 3).
Diabetes augments the relationship between themetabolic derange-
ment and arterial stiffness. The wide pulse pressure is a marker of the
latter [26–28]. Elevated pulse pressure can predict the development of
new-onset non-insulin-dependent diabetes [29]. This emphasizes the
bidirectional relationship between arterial stiffness, reﬂected pressure
waves and diabetes [30].
Among the fatalities, there were more deaths from stroke than from
any other causes. As seen in the Kaplan–Meier plot, patients with stroke
being an initial clinical presentation as hypertensive crisis had the
highest tendency to die during the ﬁrst admission (Fig. 1). The presence
of elevated pulse pressure during acute stroke carries dismal prognosis
[31,32]. Acutemortality attributed to stroke-related hypertensive emer-
gencywas not signiﬁcant between diabetics and nondiabetics. In regard
to nonfatal events, thereweremore strokes among the diabetic patients
beyond the ﬁrst presentation.
Hypertensive left ventricular failure dominated the mortality in
diabetics at the initial clinical presentation (Table 2). Diabetics with
hypertensive left ventricular failure sustained a progressive decline in
survival rate throughout the study (Fig. 2). The distinctive pathophysi-
ology of acute heart failure with marked blood pressure remains
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order [33,34]. Some evidence favors the presence of prolonged neuro-
hormonal and inﬂammatory reaction that increases arterial stiffness. A
steep increase in the afterload ensues, triggering acute left ventricular
failure. The evidence of persistent neurohormonal and inﬂammatory ac-
tivation beyond the acute episode is accumulating [35–37].
Persistent indolent inﬂammation can partially explain the sustained
high readmission and mortality rates observed among our diabetic
patients who had left ventricular failure hypertensive crises.
Kidney dysfunction was an independent predictor of mortality in
our study (Fig. 1). Patients with renal impairment manifested mortality
drift as early as ten months from the initial clinical presentation. The
intimate relationship between cardiovascular disease and renal impair-
ment is well-known and is even more intense with heart failure [38].
Diabetic patients with hypertensive crisis had recurrent admissions
with worsening renal function (Table 2). In patients with hypertensive
heart failure, the kidney is both the victim and offender. Among patients
admitted with heart failure, Forman et al. identiﬁed admission SBP
above 160 mg, diabetes mellitus and history of congestive heart failure
as predictors of worsening renal function. Hospital deaths, complica-
tions, and longer hospital stays were greater among the patients with
worsening renal function [39].
In our study, renal impairment was a strong predictor of mortality
among patients with hypertensive crisis. This ﬁnding is consistent
with those of previous studies. Sub-analysis of the STAT registry (Study-
ing the Treatment of Acute Hypertension) found chronic kidney disease
to be a common comorbidity in patientswith acute severe hypertension
[40].
Moreover, acute kidney injury is associated with a greater risk of
mortality and of acute heart failure. Patients admitted with malignant
hypertension; if proteinurea was present, and their serum creatinine
(N200 μmol/L) at presentation, their median survival time is shortened
[41].6. Limitations
Our study is subject to inherent limitations that should be addressed.
The degree of renal impairmentwas not stratiﬁed according to severity.
However, a large body of evidence stresses that with acute severe
hypertension, any degree of acute kidney injury is associated with a
greater risk of morbidity and mortality [40]. Second, blood pressure
medications and degree of blood pressure control at follow-up were
not studied, and their relationship to the outcomes was not analyzed.
It is unknown whether the prognoses might have been altered. This
aspect should be veriﬁed in future studies on hypertensive crisis. With
the available evidence, patients with hypertensive urgency whose
blood pressure was controlled after their initial clinical presentations
yet sustained more cardiovascular events in comparison with their
matching controls [16].7. Conclusion
Patients with hypertensive crisis are at risk of developing both fatal
and nonfatal cardiovascular events. Hypertensive crisis with diabetes
is a fatal blend. Hypertensive urgency in a diabetic is the equivalent of
hypertensive emergency in non-diabetics. Hypertensive urgency can
be a dormant hypertensive emergency. Evidence of left ventricular
hypertrophy or renal impairment during the urgency conceals hyper-
tensive emergency. The best strategy to ameliorate the poor prognosis
of hypertensive crisis is to prevent it.Conﬂict of interest
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